Document is current
Any future updates will be listed below
-
Authors
Jungwirth, J. https://orcid.org/0009-0008-8142-5874
von Rotz, R. https://orcid.org/0000-0003-4087-3650
Dziobek, I.
Vollenweider, F. X. https://orcid.org/0000-0001-9053-6164
Preller, K. H. https://orcid.org/0000-0003-0413-7672
-
Funding
Funding for this research was provided by:
Heffter Research Institute (DEP19-12, DEP19-12)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (320030_169260)
Swiss Neuromatrix Foundation
- License Information
-
More Information
Article History
Received: 30 May 2024
Revised: 22 November 2024
Accepted: 9 December 2024
First Online: 18 December 2024
Competing interests
: R.v.R. is currently an employee of and owns stock in Reconnect Labs AG. J.J. received honoraria for lectures and advisory board participation from Janssen Switzerland. K.H.P. is currently an employee of Boehringer Ingelheim GmbH & Co KG, and received honoraria for lectures from Johns Hopkins Medical School, USA, and California Institute of Integral Studies, USA, and is currently Chief Scientist and on the Board of Directors for the Heffter Research Institute, and scientific advisor for the MIND foundation. F.X.V. is currently on the Board of Directors of the Heffter Research Institute, and scientific advisor for the USONA Institute and the MIND Foundation. All other contributors to this manuscript declare no conflicting interests.
: All methods in this study were performed in accordance with the relevant guidelines and regulations including ICH GCP guidelines, the Swiss Clinical Trials Ordinance (ClinO), and the declaration of Helsinki. Approval for the study was granted by the Cantonal Ethics Committee, Zurich, Switzerland (Reference Number: PB-2018-00174) the Swiss Agency for Therapeutic Products (Swissmedic), and the Federal Office of Public Health (FOPH). Informed consent was obtained from all participants prior to their inclusion in the study.
